GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 9 [PMID: 38687966] | Example 95 [US20220257563] | N-(Methoxycarbonyl)-3-methyl-L-valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-L-prolinamide | PF-07817883 | PF07817883
Compound class:
Synthetic organic
Comment: PF-07817883 is an oral SARS-CoV-2 3CL (main) protease (Mpro) inhibitor. The compound and its use are claimed in patent US20220257563A1 [4]. We matched this chemical structure to the INN ibuzatrelvir from proposed INN list 129, and its formal disclosure in [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Ibuzatrelvir (ibuzatrelvir) is claimed to be devoid of off-target effects on drug metabolising cytochrome P450s [2]. For example, nirmatrelvir has to be co-adminstered with the CYP450 inhibitor ritonavir to get around its limited metabolic stability, and development of the COVID Moonshot lead DNDI-6510 was terminated as it suffered from clearance issues due to activation of CYP3A4. |
Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|